MARKET

MRKR

MRKR

MARKER THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.714
-0.037
-2.09%
Opening 10:53 12/02 EST
OPEN
1.740
PREV CLOSE
1.750
HIGH
1.750
LOW
1.670
VOLUME
33.88K
TURNOVER
--
52 WEEK HIGH
3.430
52 WEEK LOW
1.320
MARKET CAP
82.29M
P/E (TTM)
-3.3757
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 2d ago
Marker Therapeutics To Present At Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sept. 22
HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for
Benzinga · 09/17 11:05
Marker Therapeutics Q2 EPS $(0.14) Down From $(0.12) YoY, Sales $466.79K
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.14) per share. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $466.79 thousand
Benzinga · 08/10 20:01
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corp
PR Newswire · 08/10 20:00
Marker Therapeutics Announces New Manufacturing Facility To Support Clinical Development Of MultiTAA-Specific T Cell Therapy Product Candidates
HOUSTON, June 30, 2020 /PRNewswire/ --Marker Therapeutics, Inc.(NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the
Benzinga · 06/30 11:08
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that
PR Newswire · 06/30 11:00
Marker Therapeutics Receives USAN Approval For Zelenoleucel
HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the
Benzinga · 06/23 11:03
Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that
PR Newswire · 06/23 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRKR. Analyze the recent business situations of MARKER THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRKR stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 17.36M
% Owned: 36.15%
Shares Outstanding: 48.03M
TypeInstitutionsShares
Increased
13
324.09K
New
14
-165.18K
Decreased
17
286.43K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
+0.58%
Key Executives
Chairman/Independent Director
Frederick Wasserman
President/Chief Executive Officer/Director
Peter Hoang
Chief Financial Officer
Anthony Kim
Chief Accounting Officer/Chief Financial Officer/Treasurer/Secretary
Michael Loiacono
Vice President
Nadia Agopyan
Vice President
Gerald Garrett
Vice President
Tsvetelina Hoang
Vice President
Anna Szymanska
Other/Director
Juan Vera
Other
Mythili Koneru
Independent Director
David Eansor
Independent Director
Steven Elms
Independent Director
David Laskow-Pooley
Independent Director
John Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRKR
Marker Therapeutics, Inc., formerly TapImmune Inc., is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. It combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. Its core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Marker Therapeutics Inc stock information, including NASDAQ:MRKR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRKR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRKR stock methods without spending real money on the virtual paper trading platform.